The FDA just put a pause on a cutting-edge gene editing trial that hadn't started yet — and the company's stock is dropping (CRSP, VRTX)

CRISPR

  • The FDA just put a hold on one of the first trials to test the CRISPR gene-editing technology in humans. The trial hadn’t begun yet. 
  • The trial, run by CRISPR Therapeutics and Vertex Pharmaceuticals, plans to look at how the gene-editing technology works to treat patients with sickle cell disease. The trial has been put on hold “pending the resolution of certain questions that will be provided by the FDA.” 
  • CRISPR’s stock fell as much as 19% after hours on Wednesday, while Vertex was largely unchanged after-hours. 

Screen Shot 2018 05 30 at 5.55.28 PM

Join the conversation about this story »

NOW WATCH: Take a look inside this avocado-only restaurant

Read the full article from it’s original source: http://uk.businessinsider.com/crispr-therapeutics-and-vertex-fda-clinical-hold-on-gene-editing-trial-2018-5

Share this
Share on FacebookTweet about this on TwitterShare on Google+Pin on PinterestShare on LinkedInShare on Reddit